<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <title>Mallinckrodt / Endo Timeline – Keenova & Par Health</title>
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta
    name="description"
    content="Chronological timeline of Mallinckrodt and Endo: opioid litigation backdrop, bankruptcy filings, emergence, merger and spin-off into Keenova and Par Health."
  />
  <link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&display=swap" rel="stylesheet" />
  <link rel="stylesheet" href="style.css" />
</head>
<body>
<header>
  <div class="nav-inner">
    <div class="brand">
      <div class="brand-logo"></div>
      <div>
        <div class="brand-text-main">Keenova / Par Health</div>
        <div class="brand-text-sub">Mallinckrodt &amp; Endo – Timeline</div>
      </div>
    </div>
    <button class="nav-toggle" aria-label="Toggle navigation">
      <span></span>
      <span></span>
    </button>
    <nav class="nav-links">
      <a href="index.html">Overview</a>
      <a href="timeline.html">Timeline</a>
      <a href="litigation.html">Litigation</a>
      <a href="sources.html" class="nav-cta">Sources</a>
    </nav>
  </div>
</header>

<main class="page-shell">
  <section class="section">
    <div class="section-header">
      <div>
        <div class="section-kicker">Chronology</div>
        <h2 class="section-title">Key events: litigation, bankruptcy, merger and spin-off</h2>
      </div>
      <p class="section-subtitle">
        Dates and descriptions below are drawn from bankruptcy-related filings, state attorney general summaries, and
        financial/news reporting linked in the Sources page.
      </p>
    </div>

    <div class="card">
      <div class="card-header">
        <h3 class="card-title">Condensed narrative timeline</h3>
        <p class="card-subtitle">Mallinckrodt, Endo, Keenova &amp; Par Health</p>
      </div>
      <div class="card-body">
        <div class="timeline">
          <div class="timeline-item">
            <div class="timeline-dot"></div>
            <div class="timeline-label">
              Pre-bankruptcy opioid settlements and scrutiny
              <span class="timeline-date">2016–2020</span>
            </div>
            <div class="timeline-body">
              Mallinckrodt, described by several state attorneys general as one of the largest generic opioid manufacturers in
              the U.S., negotiates a tentative national settlement framework around 2020, under which it agrees to contribute
              about $1.6&nbsp;billion in structured payments to an opioid abatement trust for states, local governments and tribal
              entities.<sup> (California &amp; North Carolina AGs)</sup> At the same time, the company faces separate federal and state
              actions over Medicaid rebates and pricing of its non-opioid Acthar product.<sup> (DOJ, state AG releases)</sup>
            </div>
          </div>

          <div class="timeline-item">
            <div class="timeline-dot"></div>
            <div class="timeline-label">
              First Mallinckrodt Chapter 11
              <span class="timeline-date">October&nbsp;2020 – June&nbsp;2022</span>
            </div>
            <div class="timeline-body">
              In October&nbsp;2020, Mallinckrodt files for Chapter&nbsp;11 protection in the United States. Coverage from BioPharma Dive
              and others notes that the filing comes “amid U.S. opioid litigation” and Acthar-related pressures.<sup> (BioPharma Dive)</sup>
              A plan confirmed in early 2022 and effective June&nbsp;16&nbsp;2022 creates the Mallinckrodt Opioid Master Disbursement
              Trust&nbsp;II (MDT&nbsp;II), a “hub” trust to receive settlement funds and direct them into a network of creditor trusts for
              governments, tribes, hospitals and individuals.<sup> (MDT&nbsp;II, CA AG)</sup>
            </div>
          </div>

          <div class="timeline-item">
            <div class="timeline-dot"></div>
            <div class="timeline-label">
              Endo files for Chapter 11
              <span class="timeline-date">August&nbsp;2022</span>
            </div>
            <div class="timeline-body">
              Endo International files for Chapter&nbsp;11 in August&nbsp;2022, with Reuters and state AGs citing roughly $8&nbsp;billion in
              debt and extensive opioid-related exposure tied to products such as Opana&nbsp;ER.<sup> (Reuters, CA AG, Kentucky AG)</sup>
              Later, California’s Attorney General and the Endo Public Opioid Trust describe a settlement structure in which
              hundreds of millions of dollars are dedicated to opioid abatement via a public trust.<sup> (Endo Public Opioid Trust, CA AG)</sup>
            </div>
          </div>

          <div class="timeline-item">
            <div class="timeline-dot"></div>
            <div class="timeline-label">
              Second Mallinckrodt filing
              <span class="timeline-date">August&nbsp;2023</span>
            </div>
            <div class="timeline-body">
              After emerging from its first Chapter&nbsp;11 and making an initial $450&nbsp;million payment to MDT&nbsp;II, Mallinckrodt
              misses a subsequent payment and announces a second, pre-packaged Chapter&nbsp;11 filing in August&nbsp;2023. Reporting
              from the Washington Post and Reuters highlights that the new plan will cut nearly $1&nbsp;billion from the original
              opioid settlement obligations and sharply reduce other debt, while cancelling existing equity.<sup> (Washington Post, Reuters, MDT&nbsp;II)</sup>
            </div>
          </div>

          <div class="timeline-item">
            <div class="timeline-dot"></div>
            <div class="timeline-label">
              Mallinckrodt’s second plan confirmed
              <span class="timeline-date">October–November&nbsp;2023</span>
            </div>
            <div class="timeline-body">
              In October&nbsp;2023, a U.S. bankruptcy court approves Mallinckrodt’s second plan, cutting about $1&nbsp;billion from the
              opioid settlement and trimming nearly $2&nbsp;billion in other debt.<sup> (Reuters)</sup> Davis&nbsp;Polk’s deal summary notes
              that Mallinckrodt emerges from Chapter&nbsp;11 in November&nbsp;2023 with a new mix of “take-back” debt and equity held
              largely by its first- and second-lien lenders.<sup> (Davis&nbsp;Polk)</sup>
            </div>
          </div>

          <div class="timeline-item">
            <div class="timeline-dot"></div>
            <div class="timeline-label">
              Endo’s Chapter 11 plan and opioid trust funding
              <span class="timeline-date">March&nbsp;2024</span>
            </div>
            <div class="timeline-body">
              Reuters reports that in March&nbsp;2024 a U.S. court approves Endo’s Chapter&nbsp;11 plan, transferring more than 95% of
              the reorganized equity to lenders and dedicating around $600&nbsp;million toward opioid and tax-related settlements,
              including hundreds of millions of dollars for the Endo Public Opioid Trust.<sup> (Reuters, CA AG, Endo Public Opioid Trust)</sup>
              DOJ press releases and additional coverage describe a separate criminal case in which Endo Health Solutions is
              ordered to pay over $1.5&nbsp;billion in fines and forfeiture related to misbranded Opana&nbsp;ER.<sup> (DOJ)</sup>
            </div>
          </div>

          <div class="timeline-item">
            <div class="timeline-dot"></div>
            <div class="timeline-label">
              Merger announcement: Mallinckrodt &amp; Endo
              <span class="timeline-date">March&nbsp;13&nbsp;2025</span>
            </div>
            <div class="timeline-body">
              Financial Times and Reuters report that Mallinckrodt and Endo agree to merge in a nearly $7&nbsp;billion transaction.
              According to these outlets, Endo shareholders are slated to receive $80&nbsp;million in cash and about 49.9% of the
              combined company, with Mallinckrodt investors retaining approximately 50.1%, and the new group expects about
              $3.6&nbsp;billion in 2025 revenue and a NYSE listing.<sup> (FT, Reuters, MarketWatch, Investopedia)</sup>
            </div>
          </div>

          <div class="timeline-item">
            <div class="timeline-dot"></div>
            <div class="timeline-label">
              Merger closing
              <span class="timeline-date">July&nbsp;31&nbsp;2025</span>
            </div>
            <div class="timeline-body">
              Mallinckrodt’s website states that on July&nbsp;31&nbsp;2025, Mallinckrodt and Endo “joined together to better serve
              patients and customers,” marking the closing of the merger.<sup> (Mallinckrodt.com)</sup> Industry commentary notes that the
              combined business includes branded medicines and a large generics and sterile injectables platform.<sup> (Pharmaphorum)</sup>
            </div>
          </div>

          <div class="timeline-item">
            <div class="timeline-dot"></div>
            <div class="timeline-label">
              Spin-off of Par Health and Keenova rebrand
              <span class="timeline-date">November&nbsp;2025</span>
            </div>
            <div class="timeline-body">
              Mallinckrodt’s homepage and media reports from Pharmaphorum, BioSpace and Fierce Pharma describe a subsequent
              separation in which the combined generics and sterile injectables business is spun off as Par Health and the
              remaining specialty therapeutics business adopts the Keenova Therapeutics name.<sup> (Mallinckrodt.com, Pharmaphorum, BioSpace, FiercePharma)</sup>
              Pharmaphorum reports that Keenova has pro forma 2024 sales of around $1.7&nbsp;billion with roughly 1,600 employees,
              while Par Health records quarterly sales of roughly $337&nbsp;million with around 4,000 employees.<sup> (Pharmaphorum, BioSpace)</sup>
            </div>
          </div>
        </div>
      </div>
    </div>
  </section>

  <!-- Exhibit: high-level table -->
  <section class="section">
    <div class="section-header">
      <div>
        <div class="section-kicker">Exhibit</div>
        <h2 class="section-title">High-level 2020–2025 timeline</h2>
      </div>
      <p class="section-subtitle">
        A simple grid version of the same chronology for quick reference.
      </p>
    </div>

    <div class="card">
      <div class="card-body">
        <div class="exhibit-label">Exhibit 1</div>
        <div class="exhibit-title">Selected milestones</div>
        <p class="exhibit-caption">
          Focusing on events tied directly to opioid liabilities, restructurings and the combination.<sup> (MDT&nbsp;II, AG materials, Reuters, FT, Mallinckrodt.com)</sup>
        </p>

        <table class="exhibit-table">
          <thead>
            <tr>
              <th>Year</th>
              <th>Company</th>
              <th>Event</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>2020</td>
              <td>Mallinckrodt</td>
              <td>Files first Chapter&nbsp;11 amid large opioid and Acthar-related exposures.</td>
            </tr>
            <tr>
              <td>2022</td>
              <td>Mallinckrodt</td>
              <td>Plan effective; MDT&nbsp;II opioid trust created; settlement obligations structured over several years.</td>
            </tr>
            <tr>
              <td>2022</td>
              <td>Endo</td>
              <td>Files Chapter&nbsp;11 with about $8&nbsp;billion in debt and extensive opioid exposure.</td>
            </tr>
            <tr>
              <td>2023</td>
              <td>Mallinckrodt</td>
              <td>Files second Chapter&nbsp;11 after missing an MDT&nbsp;II payment; negotiates reduced opioid settlement and debt.</td>
            </tr>
            <tr>
              <td>2023</td>
              <td>Mallinckrodt</td>
              <td>Emerges from second Chapter&nbsp;11 with new debt and equity largely held by lenders.</td>
            </tr>
            <tr>
              <td>2024</td>
              <td>Endo</td>
              <td>Court approves Endo’s plan; lenders receive &gt;95% of equity; significant funds dedicated to Endo Public Opioid Trust.</td>
            </tr>
            <tr>
              <td>2025</td>
              <td>Both</td>
              <td>Announce and close merger valued near $7&nbsp;billion; plan for NYSE listing and $3.6&nbsp;billion in 2025 revenue.</td>
            </tr>
            <tr>
              <td>2025</td>
              <td>Keenova / Par Health</td>
              <td>Spin-off of generics and injectables business as Par Health; branded business rebranded as Keenova Therapeutics.</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </section>

  <section class="section" id="disclosure">
    <div class="disclosure">
      <p>
        <strong>Prepared by:</strong> Ted Nawrocki. This page summarizes information from public sources listed on the Sources
        page. It is informational only and should not be used as investment, legal, tax, accounting or medical advice.
      </p>
    </div>

    <footer>
      <div>© 2025 Ted Nawrocki. All rights reserved.</div>
      <div>All trademarks and company names are the property of their respective owners.</div>
    </footer>
  </section>
</main>

<script src="script.js"></script>
</body>
</html>

